MD Biosciences Showcases Its Products and Services at the 2008 APLAR Conference

Business Wire, Sept 22, 2008

MD Biosciences will be exhibiting from booth 3 at the 13(th) Congress of The Asia Pacific League of Associations for Rheumatology (APLAR) in Japan September 23 - 27, 2008

ST. PAUL, Minn. -- MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the 13th Congress of The Asia Pacific League of Associations for Rheumatology (APLAR) in Japan on September 23 - 27, 2008. APLAR focuses on providing state of the art care to patients with arthritis and other musculoskeletal diseases through continuing professional development of members, increasing the awareness and understanding about rheumatic diseases, patient advocacy and empowerment, and fostering research in the field of rheumatic diseases.

MD Biosciences, with roots in the sales of rheumatoid arthritis research reagents, will feature it's capabilities in preclinical outsourcing services such as the Collagen-Induced Arthritis (CIA), Collagen Antibody-induced Arthritis (CAIA), Adjuvant Induced arthritis (AIA), Monoarthritic Pain, along with general inflammation assays and the Senerga[R] Mode of Action Platform. MD Biosciences offers customization of all protocols as well as end-point readouts such as biomarker analysis, histology, and gene expression analysis. MD Biosciences research products featured at the conference include collagen related reagents and assays, ArthritoMab[TM] antibody cocktail, ELISAs, Aggrecan antibodies and T-cell antibodies.

In addition to the product and service offerings within Arthritis, MD Biosciences also offers products and services within other therapeutic areas such as Multiple sclerosis, Respiratory, IBD, Type I Diabetes, Endotoxic shock, Contact Dermatitis, Inflammatory and Arthritic Pain, Gliosis, and Parkinson's Disease.

Our Inflammations Discovery Service offers quick start dates and timely delivery of data, specialized scientists with experience using small molecules and biologicals, standard and specialized routes of administration, customized protocols and the development of novel models.

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.